...
首页> 外文期刊>Journal of Pharmacology and Pharmacotherapeutics >A possible case of natalizumab-dependent suicide attempt: A brief review about drugs and suicide
【24h】

A possible case of natalizumab-dependent suicide attempt: A brief review about drugs and suicide

机译:那他珠单抗依赖性自杀未遂的可能案例:药物和自杀简要回顾

获取原文
   

获取外文期刊封面封底 >>

       

摘要

β-Interferon therapy is known to be a potential trigger of suicidal behavior, but this effect has not been previously reported for other multiple sclerosis (MS) treatments, such as, natalizumab. Here we report the case history of a 32-year-old woman affected by relapsing-remitting MS, who attempted suicide during natalizumab treatment. This case suggests that a suicidal ideation might be a rare side effect of natalizumab. Nevertheless, this case represents the first evidence of the new adverse drug reaction related to natalizumab treatment. We should alert clinicians to be aware of the possibility of paradoxical activation of suicidality during its therapeutic use. The main purpose of the present article is to use this case to review the possible relationship between suicidal behavior and drugs.Keywords: Antiepileptic drugs, anti-depressive drugs, multiple sclerosis, natalizumab, suicide
机译:众所周知,β-干扰素治疗可能导致自杀行为,但以前尚未针对其他多发性硬化症(MS)治疗(如那他珠单抗)报道过这种作用。在这里,我们报告了一名患有复发缓解型MS的32岁妇女的病例史,该妇女在那他珠单抗治疗期间曾尝试自杀。该病例表明自杀观念可能是那他珠单抗的罕见副作用。然而,该病例代表了与那他珠单抗治疗有关的新的药物不良反应的第一个证据。我们应该提醒临床医生注意自杀过程中自杀性的反常激活。本文的主要目的是利用这种情况来回顾自杀行为与药物之间的可能关系。关键词:抗癫痫药,抗抑郁药,多发性硬化症,那他珠单抗,自杀

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号